Erratum (The Journal of Urology (2017) 198 (3)(552–559) (S0022534717578362) (10.1016/j.juro.2017.04.086));Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

Journal of Urology

Volumn 198, Issue 3, 2017, Pages 552-559

  Chang, Sam S ^a,b,c,d   Bochner, Bernard H ^a,b,c,d   Chou, Roger ^a,b,c,d   Dreicer, Robert ^a,b,c,d   Kamat, Ashish M ^a,b,c,d   Lerner, Seth P ^a,b,c,d   Lotan, Yair ^a,b,c,d   Meeks, Joshua J ^a,b,c,d   Michalski, Jeff M ^a,b,c,d   Morgan, Todd M ^a,b,c,d   Quale, Diane Z ^a,b,c,d   Rosenberg, Jonathan E ^a,b,c,d   Zietman, Anthony L ^a,b,c,d   Holzbeierlein, Jeffrey M ^a,b,c,d  

^a American Urological Association   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c American Society of Radiation Oncology   (United States)

^d Society of Urologic Oncology   (United States)

Author keywords

cystectomy; drug therapy; radiotherapy; urinary bladder neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT;

AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL EVALUATION; CYSTECTOMY; EVIDENCE BASED PRACTICE; FOLLOW UP; HEALTH CARE QUALITY; HISTOLOGY; HUMAN; MEDICAL RESEARCH; MEDICAL SOCIETY; MUSCLE INVASIVE BLADDER CANCER; NEOADJUVANT CHEMOTHERAPY; NONMETASTATIC MUSCLE INVASIVE BLADDER CANCER; PATIENT COUNSELING; PATIENT SELECTION; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; QUALITY OF LIFE; SYSTEMATIC REVIEW; TREATMENT PLANNING; ALGORITHM; BLADDER TUMOR; CANCER STAGING; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PRACTICE GUIDELINE; TUMOR INVASION; WATCHFUL WAITING;

ALGORITHMS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYSTECTOMY; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS; WATCHFUL WAITING;

EID: 85025105329     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2017.09.002     Document Type: Erratum

References (45)

1. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2017. CA Cancer J Clin, 67, 2016, 7.
2. Smith, A.B., Deal, A.M., Woods, M.E., et al. Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base. BJU Int, 114, 2014, 719.
3. Burger, M., Catto, J.W., Dalbagni, G., et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol, 63, 2013, 234.
4. Charlton, M.E., Adamo, M.P., Sun, L., et al. Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: a review of SEER data, 2004-2010. Cancer, 120, 2014, 3815.
5. Freedman, N.D., Silverman, D.T., Hollenbeck, A.R., et al. Association between smoking and risk of bladder cancer among men and women. JAMA, 306, 2011, 737.
6. Samanic, C., Kogevinas, M., Dosemeci, M., et al. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev, 15, 2006, 1348.
7. Abern, M.R., Dude, A.M., Tsivian, M., et al. The characteristics of bladder cancer after radiotherapy for prostate cancer. Urol Oncol, 31, 2013, 1628.
8. Rothman, N., Garcia-Closas, M., Chatterjee, N., et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet, 42, 2010, 978.
9. Koppie, T.M., Serio, A.M., Vickers, A.J., et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer, 112, 2008, 2384.
10. Lotan, Y., Amiel, G., Boorjian, S.A., et al. Comprehensive handbook for developing a bladder cancer cystectomy database. Urol Oncol, 31, 2013, 812.
11. Marshall, V.F., The relation of the preoperative estimate to the pathologic demonstration of the extent of vesicle neoplasms. J Urol, 68, 1952, 714.
12. Culp, S.H., Dickstein, R.J., Grossman, H.B., et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol, 191, 2014, 40.
13. Galsky, M.D., Hahn, N.M., Rosenberg, J., et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol, 12, 2011, 211.
14. Koie, T., Ohyama, C., Yamamoto, H., et al. Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer. Med Oncol, 31, 2014, 949.
15. Leow, J.J., Martin-Doyle, W., Rajagopal, P.S., et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol, 66, 2014, 42.
16. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst Rev, 19, 2006, CD06018.
17. Stenzl, A., Witjes, J.A., Comperat, E., Guidelines on bladder cancer muscle-invasive and metastatic. EAU, 2012.
18. Schoenberg, M.P., Walsh, P.C., Breazeale, D.R., et al. Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year follow-up. J Urol, 155, 1996, 490.
19. Shabsigh, A., Korets, R., Vora, K.C., et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol, 55, 2009, 164.
20. Lowrance, W.T., Rumohr, J.A., Chang, S.S., et al. Contemporary open radical cystectomy: analysis of perioperative outcomes. J Urol, 179, 2008, 1313.
21. Collins, J.W., Patel, H., Adding, C., et al. Enhanced recovery after robot-assisted radical cystectomy: EAU Robotic Urology Section Scientific Working Group consensus view. Eur Urol, 70, 2016, 649.
22. Xu, W., Daneshmand, S., Bazargani, S.T., et al. Postoperative pain management after radical cystectomy: comparing traditional versus enhanced recovery protocol pathway. J Urol, 194, 2015, 1209.
23. Leissner, J., Ghoneim, M.A., Abol-Enein, H., et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol, 171, 2004, 139.
24. Vazina, A., Dugi, D., Shariat, S.F., et al. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol, 171, 2004, 1830.
25. Abdollah, F., Sun, M., Schmitges, J., et al. Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. BJU Int, 109, 2012, 1147.
26. Herr, H.W., Bochner, B.H., Dalbagni, G., et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol, 167, 2002, 1295.
27. Konety, B.R., Joslyn, S.A., O'Donnell, M.A., Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol, 169, 2003, 946.
28. Shirotake, S., Kikuchi, E., Matsumoto, K., et al. Role of pelvic lymph node dissection in lymph node-negative patients with invasive bladder cancer. Jpn J Clin Oncol, 40, 2010, 247.
29. Herr, H.W., Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol, 54, 2008, 126.
30. Herr, H.W., Bajorin, D.F., Scher, H.I., Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol, 16, 1998, 1298.
31. Holzbeierlein, J.M., Lopez-Corona, E., Bochner, B.H., et al. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol, 172, 2004, 878.
32. Duncan, W., Quilty, P.M., The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage x-ray therapy. Radiother Oncol, 7, 1986, 299.
33. Blandy, J.P., Jenkins, B.J., Fowler, C.G., et al. Radical radiotherapy and salvage cystectomy for T2/3 cancer of the bladder. Prog Clin Biol Res, 260, 1988, 447.
34. Jenkins, B.J., Caulfield, M.J., Fowler, C.G., et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol, 62, 1988, 342.
35. Gospodarowicz, M.K., Rider, W.D., Keen, C.W., et al. Bladder cancer: long term follow-up results of patients treated with radical radiation. Clin Oncol, 3, 1991, 155.
36. Jahnson, S., Pedersen, J., Westman, G., Bladder carcinoma - a 20-year review of radical irradiation therapy. Radiother Oncol, 22, 1991, 111.
37. Fossa, S.D., Waehre, H., Aass, N., et al. Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. A retrospective analysis of 317 patients. Cancer, 72, 1993, 3036.
38. Coppin, C., Gospodarowicz, M., James, K., et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 14, 1996, 2901.
39. Zietman, A.L., Grocela, J., Zehr, E., et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology, 58, 2001, 380.
40. Hall, M.C., Koch, M.O., McDougal, W.S., Metabolic consequences of urinary diversion through intestinal segments. Urol Clin North Am, 18, 1991, 725.
41. Harraz, A.M., Mosbah, A., El-Assmy, A., et al. Renal function evaluation in patients undergoing orthotopic bladder substitution: a systematic review of literature. BJU Int, 114, 2014, 484.
42. Amini, E., Djaladat, H., Long-term complications of urinary diversion. Curr Opin Urol, 25, 2015, 570.
43. Krajewski, W., Piszczek, R., Krajewska, M., et al. Urinary diversion metabolic complications - underestimated problem. Adv Clin Exp Med, 23, 2014, 633.
44. Tan, W.S., Lamb, B.W., Kelley, D., Complications of radical cystectomy and orthotopic reconstruction. Adv Urol, 2015, 2015, 323157.
45. Van der Aa, F., Joniau, S., Van Den Branden, V.D., et al. Metabolic changes after urinary diversion. Adv Urol, 2011, 2011.